ELANElanco Animal Health Incorporated
Is the price fair?
Priced for +11% a year vs +5% a year delivered. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~11% a year FCF growth. The price demands more than its three-year revenue growth of 5% a year, priced for acceleration.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ELAN's price assumes
Elanco Animal Health Incorporated did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 2.24× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 3.4%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- +11%
Growth the price implies · The price pays for +11% free cash flow growth a year for a decade; revenue has grown 5.1% a year over the last three.
- Price / book
- 1.71
Price / book · today's price, trailing year to Jun 30, 2026
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 1.71
- EV / salestoday's price, trailing year to Jun 30, 2026
- 2.92
- Free cash flow, trailing twelve months
- $379M
- Market capitalisation499.6 million shares, counted Aug 3, 2026
- $11.3B
- 3-year revenue growth
- +5.1%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Drug Manufacturers, Specialty & Generic
Ranks #19 of 39 by RyuScore